Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

This study of bone marrow specimens from patients with acute myelogenous leukemia (AML) found that nucleophosmin (NPM), a nuclear protein, was displaced into the cytoplasm in about 60 percent of patients with a normal karyotype. These patients had a mutated NPM gene. Their disease may constitute a d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2005-01, Vol.352 (3), p.254-266
Hauptverfasser: Falini, Brunangelo, Mecucci, Cristina, Tiacci, Enrico, Alcalay, Myriam, Rosati, Roberto, Pasqualucci, Laura, La Starza, Roberta, Diverio, Daniela, Colombo, Emanuela, Santucci, Antonella, Bigerna, Barbara, Pacini, Roberta, Pucciarini, Alessandra, Liso, Arcangelo, Vignetti, Marco, Fazi, Paola, Meani, Natalia, Pettirossi, Valentina, Saglio, Giuseppe, Mandelli, Franco, Lo-Coco, Francesco, Pelicci, Pier-Giuseppe, Martelli, Massimo F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study of bone marrow specimens from patients with acute myelogenous leukemia (AML) found that nucleophosmin (NPM), a nuclear protein, was displaced into the cytoplasm in about 60 percent of patients with a normal karyotype. These patients had a mutated NPM gene. Their disease may constitute a distinct subtype of AML. This study of bone marrow specimens from patients with acute myelogenous leukemia found that nucleophosmin, a nuclear protein, was displaced into the cytoplasm in about 60 percent of patients with a normal karyotype. Acute myelogenous leukemia (AML), the most common form of acute leukemia in adults, is a heterogeneous group of diseases that are curable in about 30 percent of cases. Cytogenetic analysis assigns AML to different prognostic groups 1 ; some subtypes, such as acute promyelocytic leukemia with a t(15;17) translocation (subtype M3 according to the French–American–British [FAB] classification), are amenable to specific therapies. However, no chromosomal abnormality is visible by conventional karyotyping in 40 to 50 percent of cases. Attempts to stratify such cases on the basis of microarrays of complementary DNA 2 , 3 have succeeded in associating gene-expression patterns with differences in . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa041974